Wakita Hisashi, Ohkuro Masayoshi, Ishii Naoto, Hishinuma Ieharu, Shirato Manabu
Tsukuba Research Laboratories, Eisai Co. Ltd., Ibaraki, Japan.
Exp Dermatol. 2015 Mar;24(3):215-6. doi: 10.1111/exd.12606.
E6005, a potent, selective phosphodiesterase (PDE) 4 inhibitor, has been developed as a novel topical agent of atopic dermatitis (AD). It has been shown to inhibit itching in patients with AD as well in mouse models. To study the mechanism underlying the anti-pruritic effect of E6005, we examined its effect on the activation of dorsal root ganglion (DRG) neurons associated with the itch sensation. Depolarization of DRG neurons by a transient receptor potential vanilloid 1 (TRPV 1) activator, capsaicin was attenuated by E6005 as well as by a 3',5'-cyclic adenosine monophosphate (cAMP) elevator, forskolin. E6005 elevated intracellular levels of cAMP in DRG cells. Taken together, these results suggest that E6005 suppresses TRPV1-mediated C-fibre depolarization through elevation of cAMP levels, thereby exerting an anti-pruritic effect. Thus, E6005 shows the potential to be a new agent for managing pruritus in various skin disorders, including AD.
E6005是一种强效、选择性磷酸二酯酶(PDE)4抑制剂,已被开发为一种新型特应性皮炎(AD)局部用药。在AD患者以及小鼠模型中,它均已显示出抑制瘙痒的作用。为研究E6005止痒作用的潜在机制,我们检测了其对与瘙痒感觉相关的背根神经节(DRG)神经元激活的影响。E6005以及3',5'-环磷酸腺苷(cAMP)增强剂福斯高林均可减弱由瞬时受体电位香草酸亚型1(TRPV 1)激活剂辣椒素引起的DRG神经元去极化。E6005可提高DRG细胞内的cAMP水平。综合这些结果表明,E6005通过提高cAMP水平来抑制TRPV1介导的C纤维去极化,从而发挥止痒作用。因此,E6005显示出成为治疗包括AD在内的各种皮肤疾病瘙痒的新型药物的潜力。